A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2018
At a glance
- Drugs GSK-3358699 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 18 Jun 2018 Planned End Date changed from 5 Aug 2019 to 29 Jul 2019.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Feb 2018 Planned End Date changed from 30 May 2019 to 5 Aug 2019.